Atlas et al. in $30m round for Replimune

Investing alongside the new backer were Forbion Capital Partners and Omega Funds, which had both supported Replimune previously at the seed stage. The company was founded in April this year.

Replimune intends to progress its oncolytic immunotherapies through clinical trials and to eventually combine them with a process named checkpoint blockade at an early stage of clinical development.

Besides developing its own products, Replimune will also aim to pursue a partnering strategy with companies having successfully developed checkpoint blockade or other complementary immuno-oncology drugs.

Company
Established in early 2015, Replimune is headquartered in Oxford and also has a presence in Cambridge in the US. It focuses on oncolytic immunotherapy, a new class of cancer therapeutics that exploits the ability of viruses to selectively replicate in and kill tumour tissue.

People
Jason Rhodes led the deal for Atlas – he will join the board of Replimune, as will Omega's Otello Stampacchia and Forbion's Sander Slootweg.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Early-stage
• Healthcare
• Atlas Venture
• Venture
• United Kingdom